Former FDA Cosmetics Director Weighs In On Senator Hatch's Draft FCSMA
This article was originally published in The Rose Sheet
Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.
You may also be interested in...
ICMAD leadership agrees with Bailey that, now more than ever before, the pieces are in place for cosmetics reform legislation to reach the finish line. At the same time, the small-business advocate remains opposed to leading proposals, signaling the significant distance that negotiations may still have to go.
FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.
Alexandra Kowcz is the Personal Care Product Council's new executive VP for science, effective Jan. 29, 2018. She brings to the trade association extensive experience from R&D and manager roles at Beiersdorf and P&G, as well as drug firms and cosmetic ingredient supplier Centerchem.